<DOC>
	<DOCNO>NCT02753595</DOCNO>
	<brief_summary>The primary objective study follow : For Phase 1b - determine safety tolerability recommend Phase 2 dose ( RP2D ) eribulin mesylate combination PEGylated recombinant human hyaluronidase ( PEGPH20 ) participant Human Epidermal Growth Factor Receptor ( HER2 ) -negative metastatic breast cancer ( MBC ) previously treat two line systemic anticancer therapy metastatic setting . For Phase 2 - evaluate objective response rate ( ORR ) eribulin mesylate combination PEGPH20 participants HER2-negative , High-Hyaluronan ( HA ) -high , MBC previously treat 2 line systemic anticancer therapy metastatic setting .</brief_summary>
	<brief_title>Study Eribulin Mesylate Combination With PEGylated Recombinant Human Hyaluronidase ( PEGPH20 ) Versus Eribulin Mesylate Alone Subjects With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Negative , High-Hyaluronan ( HA ) Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description>Phase 1b occur two part : Part 1 : Run-in safety cohort ( ) ( dose level 1 , 0 , -1 , necessary ) 6 participant conduct RP2D determine . The purpose run-in safety cohort ( ) study safety 2-drug combination determine RP2D . Dose limit toxicity ( DLT ) assess first cycle determine RP2D eribulin mesylate combination PEGPH20 . Part 2 ( Phase 1b `` Expansion Part '' ) : A total 12 additional participant enrol RP2D determine Part 1 ( use Phase 1b criterion , i.e. , participant previously treat 2 line systemic anticancer therapy ) order ass safety profile combination identify potential safety signal incidence thromboembolic event population . In Phase 2 , participant stratify triple negative breast cancer ( TNBC ) status randomize 1:1 receive eribulin mesylate PEGPH20 establish RP2D level eribulin mesylate alone 1.4 milligram per square meter ( mg/m^2 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Inclusion Criteria 1 . Metastatic Her2 breast cancer 2 . Up 2 prior line cytotoxic target anticancer therapy metastatic disease 3 . Measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.1 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Exclusion Criteria 1 . Less 6 month since prior neoadjuvant/adjuvant chemotherapy 2 . Known central nervous system ( CNS ) disease , except participant treat brain metastasis stable least 1 month , evidence progression hemorrhage treatment ongoing requirement corticosteroid , ascertain clinical examination brain imaging ( MRI CT ) screen period 3 . Previous history current evidence deep vein thrombosis ( DVT ) , hereditary thrombophilic syndrome , pulmonary embolism ( PE ) , cerebral vascular accident ( CVA ) , transient ischemic attack ( TIA ) , atrial fibrillation ( AF ) , active carotid artery disease require treatment 4 . Treatment chemotherapy , hormonal , biological therapy within previous 3 week , radiation small molecule target therapy within previous 2 week precede informed consent 5 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PEGylated Recombinant Human Hyaluronidase</keyword>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>E7389</keyword>
	<keyword>PEGPH20</keyword>
	<keyword>Human Epidermal Growth Factor Receptor 2-Negative</keyword>
	<keyword>High-Hyaluronan</keyword>
</DOC>